Chemotherapy-Induced Peripheral Neuropathy: Causative Agents, Preventative Strategies, and Treatment Approaches

References

• Shah A, Hoffman EM, Mauermann ML, Loprinzi CL, Windebank AJ, Klein CJ, Staff NP. Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. J Neurol Neurosurg Psychiatry. 2018;89(6):636–41. doi:10.1136/jnnp-2017-317215.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Common terminology criteria for adverse events version 6.0; Updated November 27, 2019 [accessed 2019 June 8]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.
   Google Scholar
• Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol. 1995;133(1):64–72. doi:10.1006/exnr.1995.1008.
   PubMed Web of Science ®Google Scholar
• Macfarlane B, Wright A, Benson H. Reversible blockade of retrograde axonal transport in the rat sciatic nerve by vincristine. J Pharm Pharmacol. 1997;49(1):97–101. doi:10.1111/j.2042-7158.1997.tb06759.x.
   PubMed Web of Science ®Google Scholar
• Sahenk Z, Brady S, Mendell J. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve. 1987;10(1):80–4. doi:10.1002/mus.880100115.
   PubMed Web of Science ®Google Scholar
• Topp K, Tanner K, Levine J. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol. 2000;424(4):563–76. doi:10.1002/1096-9861(20000904)424:4<563::AID-CNE1>3.0.CO;2-U.
   PubMed Web of Science ®Google Scholar
• Tulub A, Stefanov V. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol. 2001;28(3):191–8. doi:10.1016/S0141-8130(00)00159-8.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77. doi:10.1016/j.critrevonc.2011.04.012.
   PubMed Web of Science ®Google Scholar
• Benoit E, Brienza S, Dubois JM. Oxaliplatin, an anticancer agent that affects both Na + and K + channels in frog peripheral myelinated axons. Gen Physiol Biophys. 2006;25(3):17197725. 263-76.
   Web of Science ®Google Scholar
• Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85(5):2293–7. doi:10.1152/jn.2001.85.5.2293.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472–8. doi:10.1200/JCO.2010.33.0308.
   PubMed Web of Science ®Google Scholar
• Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013;18(1):132–8. doi:10.1007/s10147-011-0352-x.
   PubMed Web of Science ®Google Scholar
• Millennium Pharmaceuticals. Velcade (bortezomib) highlights of prescribing information. US Food and Drug Administration; Updated April 20, 2019 [accessed 2019 May 3]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf.
   Google Scholar
• Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27(21):3518–25. doi:10.1200/JCO.2008.18.3087.
   PubMed Web of Science ®Google Scholar
• Maschio M, Zarabla A, Maialetti A, Marchesi F, Giannarelli D, Gumenyuk S, Pisani F, Renzi D, Galiè E, Mengarelli A, et al. Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and α-lipoic acid in patients with multiple myeloma: preliminary data. Integr Cancer Ther. 2018;17(4):1115–24. doi:10.1177/1534735418803758.
   PubMed Web of Science ®Google Scholar
• Seattle Genetics. Adcetris (brentuximab vedotin) highlights of prescribing information. US Food and Drug Administration; Updated April 2019 [accessed 2019 Sept 5]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125388s099lbl.pdf.
   Google Scholar
• Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, Salva KA, Wood GS, Kim YH, Nagpal S, et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol. 2017;132(3):439–46. doi:10.1007/s11060-017-2389-9.
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Greggi S, Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G, Ferrau’ F, et al. Multicenter Italian Trials in Ovarian Cancer invesitgators. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14(7):1086–93. 93. doi:10.1093/annonc/mdg301.
   PubMed Web of Science ®Google Scholar
• Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14(7):2101–12. doi:10.1200/.1996.14.7.2101.
   PubMed Web of Science ®Google Scholar
• Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy–a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer. 2005;13(10):797–805. doi:10.1007/s00520-005-0782-y.
   PubMed Web of Science ®Google Scholar
• Leong SS, Tan EH, Fong KW, Wilder-Smith E, Ong YK, Tai BC, Chew L, Lim SH, Wee J, Lee KM, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2003;21(9):1767–74. doi:10.1200/JCO.2003.11.005.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol. 1997;41(2):161–6. doi:10.1007/s002800050723.
   Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253–5. doi:10.1212/01.wnl.0000249344.99671.d4.
   PubMed Web of Science ®Google Scholar
• Kautio AL, Haanpää M, Leminen A, Kalso E, Kautiainen H, Saarto T. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res. 2009;29(7):2601–6. PMID: 19596934.
   PubMed Web of Science ®Google Scholar
• Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, Tirona MT, Rowland KM, Stella PJ, Johnson JA, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98(1):195–203. doi:10.1016/S0304-3959(02)00047-7.
   PubMed Web of Science ®Google Scholar
• Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5. doi:10.1093/annonc/mdr045.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32(10):997–1005. doi:10.1200/JCO.2013.52.0536.
   PubMed Web of Science ®Google Scholar
• Salehi Z, Roayaei M. Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial. Int J Prev Med. 2015;6:104. doi:10.4103/2008-7802.169021.
   PubMed Web of Science ®Google Scholar
• Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21(5):927–31. doi:10.1200/JCO.2003.05.139.
   PubMed Web of Science ®Google Scholar
• Pace A, Giannarelli D, Galie E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A, Gaviani P, Scaioli V, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74(9):762–6. doi:10.1212/WNL.0b013e3181d5279e.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995;13(1):26–32. doi:10.1200/JCO.1995.13.1.26.
   PubMed Web of Science ®Google Scholar
• Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, et al. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890–7. doi:10.1002/cncr.28654.
   PubMed Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10(12):4055–61. doi:10.1158/1078-0432.CCR-03-0666.
   PubMed Web of Science ®Google Scholar
• Hochster H, Grothey A, Childs B. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. JCO. 2007;25(25):4028–9. doi:10.1200/JCO.2007.13.5251.
   PubMed Web of Science ®Google Scholar
• Pastori D, Carnevale R, Cangemi R, Saliola M, Nocella C, Bartimoccia S, et al. Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. J Am Heart Assoc. 2013;2(6):e000364. doi:10.1161/JAHA.113.000364.PMID: 24166490.
   PubMed Web of Science ®Google Scholar
• Kleckner IR, Kamen C, Cole C, Fung C, Heckler CE, Guido JJ, Culakova E, Onitilo AA, Conlin A, Kuebler JP, et al. Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial. Support Care Cancer. 2019;27(12):4615–25. doi:10.1007/s00520-019-04772-7.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94–102. doi:10.1016/j.cyto.2003.10.004.
   PubMed Web of Science ®Google Scholar
• Zhou Y-Q, Liu Z, Liu Z-H, Chen S-P, Li M, Shahveranov A, Ye D-W, Tian Y-K. Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation. 2016;13(1):141. doi:10.1186/s12974-016-0607-6.
   PubMed Web of Science ®Google Scholar
• Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26(10):1642–9. doi:10.1200/JCO.2007.11.6699.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(18):1941–67. doi:10.1200/JCO.2013.54.0914.
   PubMed Web of Science ®Google Scholar
• Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67. doi:10.1001/jama.2013.2813.
   PubMed Web of Science ®Google Scholar
• Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier KS, Bearden JD, Kugler JW, Hoff KL, Reddy PS, et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19(6):833–41. doi:10.1007/s00520-010-0911-0.
   PubMed Web of Science ®Google Scholar
• Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, Hopkins JO, Morrow GR. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807–14. doi:10.1007/s00520-014-2158-7.
   PubMed Web of Science ®Google Scholar
• Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. North Central Cancer Treatment Group. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 20071;110(9):2110–18. doi:10.1002/cncr.23008.
   PubMed Web of Science ®Google Scholar
• Caraceni A, Zecca E, Bonezzi C, Arcuri E, Tur RY, Maltoni M, Visentin M, Gorni G, Martini C, Tirelli W, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22(14):2909–17. doi:10.1200/JCO.2004.08.141.
   PubMed Web of Science ®Google Scholar
• Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, Lafky JM, Dentchev T, Le-Lindqwister NA, Sikov WM, et al. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017;25(11):3407–16. doi:10.1007/s00520-017-3760-2.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Cymbalta (duloxetine hydrochloride) Highlights of prescribing information. US Food and Drug Administration; Updated December 2017 [accessed 2019 May 25]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021427s050lbl.pdf.
   Google Scholar
• Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Kelaghan J, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171–8. doi:10.1002/cncr.27489.
   PubMed Web of Science ®Google Scholar
• Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35(1):31–9. doi:10.1016/j.jpainsymman.2007.02.043.
   PubMed Web of Science ®Google Scholar
• Dorsey SG, Kleckner IR, Barton D, Mustian K, O’Mara A, St Germain D, et al. The National Cancer Institute clinical trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy. J Natl Cancer Inst. 2019;111(6):531–37. doi:10.1093/jnci/djz011.
   PubMedGoogle Scholar
• Marineo G. Untreatable pain resulting from abdominal cancer: new hope from biophysics? JOP. 2003;4(1):1–10. PMID: 12555009.
   PubMedGoogle Scholar
• Argenta PA, Ballman KV, Geller MA, Carson LF, Ghebre R, Mullany SA, Teoh DGK, Winterhoff BJN, Rivard CL, Erickson BK, et al. The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: a randomized, sham-controlled clinical trial. Gynecol Oncol. 2017;144(1):159–66. doi:10.1016/j.ygyno.2016.11.013.
   PubMed Web of Science ®Google Scholar
• Vasquez S, Guidon M, McHugh E, Lennon O, Grogan L, Breathnach OS. Chemotherapy induced peripheral neuropathy: the modified total neuropathy score in clinical practice. Ir J Med Sci. 2014;183(1):53–8. doi:10.1007/s11845-013-0971-5.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, et al. A pilot randomized sham-controlled trial of MC5-a scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN). J Palliat Care. 2019. doi:10.1177/0825859719827589.
   Web of Science ®Google Scholar